Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study

被引：1
|
作者：
Gargiulo, Luigi [1 ,2 ]
Ibba, Luciano [1 ,2 ]
Bianco, Matteo [1 ,2 ]
Di Giulio, Sara [1 ,2 ]
Alfano, Alfano [1 ,2 ]
Ingurgio, Ruggero Cascio [1 ,2 ]
Facheris, Paola [1 ]
Perugini, Chiara [1 ]
Valenti, Mario [1 ,2 ]
Costanzo, Antonio [1 ,2 ]
Narcisi, Alessandra [1 ]
机构：
[1] IRCCS Humanitas Res Hosp, Dermatol Unit, Rozzano, Italy
[2] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy
来源：
JOURNAL OF DERMATOLOGICAL TREATMENT | 2024年 / 35卷 / 01期
关键词：
DOUBLE-BLIND; ADOLESCENTS; PLACEBO; ADULTS; SAFETY;
D O I：
10.1080/09546634.2024.2375102
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Effectiveness and safety of upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: A 52-week retrospective study
    Gargiulo, L.
    Ibba, L.
    Piscazzi, F.
    Alfano, A.
    Ingurgio, R. Cascio
    Valenti, M.
    Costanzo, A.
    Narcisi, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (02) : e152 - e154
  • [2] Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China
    Deng, Sisi
    Wang, Huan
    Chen, Qiquan
    Chen, Xueqin
    Song, Xiao
    Chen, Shuguang
    Kong, Minmin
    Song, Zhiqiang
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2024, 316 (06)
  • [3] Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study
    Hagino, Teppei
    Hamada, Risa
    Yoshida, Mai
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    PHARMACEUTICALS, 2024, 17 (04)
  • [4] Laboratory markers of dupilumab patients with moderate-to-severe atopic dermatitis: a single-center, real-world study
    Hawkins, K.
    Sharma, D.
    Shokrian, N.
    Piontkowski, A.
    Ungar, B.
    Guttman-Yassky, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (08) : S162 - S162
  • [5] Upadacitinib for the treatment of moderate-to-severe atopic dermatitis in real-world clinical practice
    Tran, Vanessa
    Ross, Gayle
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 11 - 11
  • [6] A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis
    Stingeni, Luca
    Bianchi, Leonardo
    Antonelli, Elettra
    Caroppo, Elena Sofia
    Ferrucci, Silvia Mariel
    Gurioli, Carlotta
    Ortoncelli, Michela
    Fabbrocini, Gabriella
    Nettis, Eustachio
    Schena, Donatella
    Napolitano, Maddalena
    Gola, Massimo
    Bonzano, Laura
    Rossi, MariaTeresa
    Belloni Fortina, Anna
    Balato, Anna
    Peris, Ketty
    Foti, Caterina
    Guarneri, Fabrizio
    Romanelli, Marco
    Patruno, Cataldo
    Savoia, Paola
    Esposito, Maria
    Russo, Filomena
    Errichetti, Enzo
    Bianchelli, Tommaso
    Bianchi, Luca
    Pellacani, Giovanni
    Feliciani, Claudio
    Offidani, Annamaria
    Corazza, Monica
    Micali, Giuseppe
    Milanesi, Nicola
    Malara, Giovanna
    Chiricozzi, Andrea
    Tramontana, Marta
    Hansel, Katharina
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (03) : E384 - E388
  • [7] Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study
    Luigi Gargiulo
    Luciano Ibba
    Andrea Cortese
    Jessica Avagliano
    Mario Valenti
    Antonio Costanzo
    Alessandra Narcisi
    Dermatology and Therapy, 2023, 13 : 651 - 660
  • [8] Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study
    Gargiulo, Luigi
    Ibba, Luciano
    Cortese, Andrea
    Avagliano, Jessica
    Valenti, Mario
    Costanzo, Antonio
    Narcisi, Alessandra
    DERMATOLOGY AND THERAPY, 2023, 13 (02) : 651 - 660
  • [9] Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study
    Torres, Tiago
    Varela, Paulo
    Bastos, Pedro Mendes
    Magina, Sofia
    Henrique, Martinha
    Ferreira, Paulo
    DRUGS IN CONTEXT, 2024, 13
  • [10] Efficacy of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Real-World Practice in a Single Center
    Bai, Juan
    Su, Wang
    Fang, Hong
    Qiao, Jianjun
    AMERICAN JOURNAL OF THERAPEUTICS, 2024, 31 (03) : e332 - e334
12345